© Copyright 2007 - 2011 www.cmvfoundation.org Federal Tax ID #: 26-0886244
| Public Awareness and Vaccine Research Support. Working Together to Eradicate Congenital CMV Disease. Member of the External Partner Group, in conjunction with the National Center on Birth Defects and Developmental Disabilities (NCBDDD) and the Centers for Disease Control and Prevention (CDC) |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| The Brendan B. McGinnis Congenital CMV Foundation is a non-profit 501 (c) (3) dedicated to raising public awareness about congenital CMV, to raise donations to support research for a vaccine for CMV, and to affect change in the medical community so that physicians will begin to test women for CMV prior to pregnancy. Ultimately, our mission is to save babies yet to be born from suffering the often devastating consequences of congenital CMV by eradicating this common but potentially life-altering virus. |
The Brendan B. McGinnis Congenital CMV Foundation is a non-profit 501(c)(3) established in 2007 by Tracy McGinnis, whose son Brendan is severely disabled and developmentally delayed due to congenital CMV. The primary goals of the foundation are to raise public awareness about congenital CMV, to raise donations to support research for a vaccine for CMV, and to affect change in the medical community so that physicians will begin to test women for CMV prior to pregnancy. Ultimately, our mission is to save babies yet to be born from suffering the potentially devastating consequences of congenital CMV. |
| About Our Foundation |
| Currently on the Board of Directors for the Brendan B. McGinnis Congenital CMV Foundation |
She has a Master's degree in Counseling with specializations in both Child and Family Therapy and in School Counseling. Tracy established the Brendan B. McGinnis Congenital CMV Foundation in 2007. It was the first non-profit foundation internationally dedicated to raising CMV awareness, and it continues to be the only foundation worldwide that isdedicated to raising both public awareness and donations for vaccine research support. Tracy named the foundation to honor her son, Brendan. It is her heart's desire to assure that, one day, no more babies will be born with congenital CMV. Brendan is her inspiration and the driving force behind the foundation's work. Tracy runs the foundation's day to day operations, including the website maintenance, awareness campaign organization, product development, and parent support networking. |
Tracy McGinnis
Ms. Crystal Thomas
Dr. Cannon is a research epidemiologist at the CDC’s National Center on Birth
Defects and Developmental Disabilities and an adjunct assistant professor at Emory
University’s School of Public Health. He specializes in research on the epidemiology
and prevention of congenital CMV. He has published papers on the national
prevalence of CMV infection, worldwide prevalence of congenital CMV infection, and
women’s and physician’s knowledge and awareness of CMV. His current interests
include promoting behavioral changes to prevent CMV infection in pregnant
women and evaluating the utility of newborn CMV screening.
Defects and Developmental Disabilities and an adjunct assistant professor at Emory
University’s School of Public Health. He specializes in research on the epidemiology
and prevention of congenital CMV. He has published papers on the national
prevalence of CMV infection, worldwide prevalence of congenital CMV infection, and
women’s and physician’s knowledge and awareness of CMV. His current interests
include promoting behavioral changes to prevent CMV infection in pregnant
women and evaluating the utility of newborn CMV screening.
Mike Cannon, Ph.D.
University School of Medicine. For twenty-five years Dr. McVoy’s research has
focused almost exclusively on cytomegalovirus. In 1993 he received his Ph.D.
in Microbiology & Immunology from Virginia Commonwealth University under
the mentorship of Stuart Adler. After post-doctoral training with Edward
Mocarski at Stanford University he returned to VCU to join the faculty in the
Department of Pediatrics. His research interests include: basic mechanisms
of viral DNA replication and maturation as potential targets for antiviral
development; viral mechanisms of immune evasion and their impact on live
vaccines; and development of novel live and subunit vaccine strategies.
focused almost exclusively on cytomegalovirus. In 1993 he received his Ph.D.
in Microbiology & Immunology from Virginia Commonwealth University under
the mentorship of Stuart Adler. After post-doctoral training with Edward
Mocarski at Stanford University he returned to VCU to join the faculty in the
Department of Pediatrics. His research interests include: basic mechanisms
of viral DNA replication and maturation as potential targets for antiviral
development; viral mechanisms of immune evasion and their impact on live
vaccines; and development of novel live and subunit vaccine strategies.
Dr. Michael McVoy
Dr. Pellett's research interests are focused on understanding the biology of
human herpesviruses and improving clinical outcomes of herpesvirus infections.
He is studying two types of molecular interactions between human
cytomegalovirus and the infected cell: how the virus manipulates cellular
microRNA populations and how the virus remodels the cell to form the
factory in which new virus particles are manufactured. He is working to identify
ways to use this information to improve the diagnosis and treatment of human
cytomegalovirus infections. Dr. Pellett earned his Ph.D. from the University of
Chicago in 1986. He served as Chief of the Herpesvirus Section at the US
Centers for Disease Control and Prevention (CDC) from 1986 until 2003, and was
Director of Herpesvirus Translational and Basic Research at the Cleveland Clinic
prior to joining Wayne State University in 2007.
human herpesviruses and improving clinical outcomes of herpesvirus infections.
He is studying two types of molecular interactions between human
cytomegalovirus and the infected cell: how the virus manipulates cellular
microRNA populations and how the virus remodels the cell to form the
factory in which new virus particles are manufactured. He is working to identify
ways to use this information to improve the diagnosis and treatment of human
cytomegalovirus infections. Dr. Pellett earned his Ph.D. from the University of
Chicago in 1986. He served as Chief of the Herpesvirus Section at the US
Centers for Disease Control and Prevention (CDC) from 1986 until 2003, and was
Director of Herpesvirus Translational and Basic Research at the Cleveland Clinic
prior to joining Wayne State University in 2007.
Dr. Philip Pellet
Dr. Mark Schleiss is the American Legion Endowed Professor of Pediatrics
and Director of the Division of Pediatric Infectious Diseases at the University of
Minnesota. His laboratory is broadly interested in the study of congenital
cytomegalovirus (CMV) transmission, including vaccines, antiviral drugs, newborn
screening, and viral pathogenesis. Dr. Schleiss has developed an animal model of
congenital CMV transmission, ideal for the study of CMV vaccines designed to
protect the fetus. Using this guinea-pig model, protection against CMV
transmission and disease can be engendered by vaccines targeting viral envelope
glycoproteins, as well as live, attenuated vaccines. The recent encouraging
results of a phase II study of a purified CMV glycoprotein in a population of young
women at high risk for primary CMV infection has validated the value of the
guinea-pig model, since preclinical studies of a similar vaccine in this model
demonstrated protection against CMV transmission to the guinea-pig fetus. Dr.
Schleiss is continuing to study a variety of vaccine strategies in this model,
toward the goal of defining optimal ways of protecting newborns against the
potentially devastating consequences of congenital CMV infection.
and Director of the Division of Pediatric Infectious Diseases at the University of
Minnesota. His laboratory is broadly interested in the study of congenital
cytomegalovirus (CMV) transmission, including vaccines, antiviral drugs, newborn
screening, and viral pathogenesis. Dr. Schleiss has developed an animal model of
congenital CMV transmission, ideal for the study of CMV vaccines designed to
protect the fetus. Using this guinea-pig model, protection against CMV
transmission and disease can be engendered by vaccines targeting viral envelope
glycoproteins, as well as live, attenuated vaccines. The recent encouraging
results of a phase II study of a purified CMV glycoprotein in a population of young
women at high risk for primary CMV infection has validated the value of the
guinea-pig model, since preclinical studies of a similar vaccine in this model
demonstrated protection against CMV transmission to the guinea-pig fetus. Dr.
Schleiss is continuing to study a variety of vaccine strategies in this model,
toward the goal of defining optimal ways of protecting newborns against the
potentially devastating consequences of congenital CMV infection.
Dr. Mark Schleiss
Crystal is mom to 5 year old Trenton, who is affected by congenital CMV. She is
contributing to CMV vaccine research. Crystal comes to the Board of Directors
with years of experience in accounting and credit management, as well as her
enthusiasm and dedication to seeing our mission statement fulfilled. She is also
the mom of a 6 year old daughter, Shelby. Crystal's projects for the Foundation
include currently working on organizing our 2011 Making Tracks Together event
for families affected by CMV, as well as upcoming CMV Awareness fundraising
campaigns.
contributing to CMV vaccine research. Crystal comes to the Board of Directors
with years of experience in accounting and credit management, as well as her
enthusiasm and dedication to seeing our mission statement fulfilled. She is also
the mom of a 6 year old daughter, Shelby. Crystal's projects for the Foundation
include currently working on organizing our 2011 Making Tracks Together event
for families affected by CMV, as well as upcoming CMV Awareness fundraising
campaigns.
